Publication related to RSI or an RSI staff member

Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.

OBJECTIVE: To describe trends in and patterns of antihypertensive drug use in a general obstetric population. STUDY DESIGN: Historical cohort study. A total of 18,117 women who gave birth in a Saskatchewan hospital between January 1, 1980 and December 31, 2005 with a diagnosis of hypertensive disorders in pregnancy were identified and included in the analysis. RESULTS: The rate of treatment with antihypertensive drugs for pregnant women with chronic hypertension rose from 19.94% in 1980-1984 to 37.63% in 2000-2005. There were similar increases in antihypertensive drug use from 1.51% to 14.47% for gestational hypertension/non-severe preeclampsia, and from 1.56% to 20.86% for severe preeclampsia/eclampsia. Methyldopa was the most frequently used drug, followed by beta-blockers, with other antihypertensive drugs accounting for about 18.43% of total uses. The use of both methyldopa and labetalol has increased in recent years while the use of other antihypertensive drugs has decreased. Other antihypertensive drugs were more commonly prescribed in earlier gestation, while methyldopa and labetalol were generally prescribed in later gestation. CONCLUSION: The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase.

Authors

  • Xie, Ri-hua, Xie RH, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Road, Guangzhou 510515, China; OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6; Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Canada K1H 8L6.

  • Guo, Yanfang, Guo Y,

  • Krewski, Daniel, Krewski D,

  • Mattison, Donald, Mattison D,

  • Nerenberg, Kara, Nerenberg K,

  • Walker, Mark C, Walker MC,

  • Wen, Shi Wu, Wen SW,

YEAR OF PUBLICATION: 2013
SOURCE: Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):281-5. doi: 10.1016/j.ejogrb.2013.09.032. Epub 2013 Oct 1.
JOURNAL TITLE ABBREVIATION: Eur J Obstet Gynecol Reprod Biol
JOURNAL TITLE: European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654 (Electronic) 0301-2115 (Linking)
VOLUME: 171
ISSUE: 2
PAGES: 281-5
PLACE OF PUBLICATION: Ireland
ABSTRACT:
OBJECTIVE: To describe trends in and patterns of antihypertensive drug use in a general obstetric population. STUDY DESIGN: Historical cohort study. A total of 18,117 women who gave birth in a Saskatchewan hospital between January 1, 1980 and December 31, 2005 with a diagnosis of hypertensive disorders in pregnancy were identified and included in the analysis. RESULTS: The rate of treatment with antihypertensive drugs for pregnant women with chronic hypertension rose from 19.94% in 1980-1984 to 37.63% in 2000-2005. There were similar increases in antihypertensive drug use from 1.51% to 14.47% for gestational hypertension/non-severe preeclampsia, and from 1.56% to 20.86% for severe preeclampsia/eclampsia. Methyldopa was the most frequently used drug, followed by beta-blockers, with other antihypertensive drugs accounting for about 18.43% of total uses. The use of both methyldopa and labetalol has increased in recent years while the use of other antihypertensive drugs has decreased. Other antihypertensive drugs were more commonly prescribed in earlier gestation, while methyldopa and labetalol were generally prescribed in later gestation. CONCLUSION: The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase.
COPYRIGHT INFORMATION: Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
LANGUAGE: eng
DATE OF PUBLICATION: 2013 Dec
DATE OF ELECTRONIC PUBLICATION: 20131001
DATE COMPLETED: 20140815
DATE REVISED: 20131209
MESH DATE: 2014/08/16 06:00
EDAT: 2013/10/22 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: S0301-2115(13)00485-5 [pii] 10.1016/j.ejogrb.2013.09.032 [doi]
OWNER: NLM

Related RSI Experts

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski

Donald Mattison

Chief Medical Officer, Senior Vice-President

Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Read More about Donald Mattison